FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology. A recombinant nucleic acid molecule for the expression of the first and second transgene containing a bidirectional promoter is described (hCMV-rhCMV promoter), functionally bound to the first transgen in one direction and to the second transgen in the opposite direction, wherein promoter hCMV-rhCMV contains: (i) an enhancer flanked by (ii) the main immediately-early human cytomegalovirus promoter (cmv promoter) on one side of the enhancer and (iii) the main immediately-early rhesus macaque cytomegalovirus promoter (rhCMV promoter) on the other side of the enhancer, wherein (iv) the first transgen is located below the hCMV promoter, and (v) the second transgen is located below the rhCMV promoter. A recombinant vector for the expression of the first and second transgene containing a recombinant nucleic acid molecule and a recombinant virus for the expression of the first and second transgene containing a recombinant nucleic acid molecule are presented. A method for obtaining a genetically stable recombinant adenovirus containing the first and second transgenes, with each of them effectively expressed, is described, in the event that an adenovirus infects a target cell, including: a) obtaining a construct containing bidirectional promoter hCMV-rhCMV, that is functionally bound to the first transgene in one direction and to the second transgene in the opposite direction; and b) this construct integration in the genome of a recombinant adenovirus. A method for the expression of at least two transgenes in a cell, including the delivery of a recombinant vector or recombinant virus to the cell, is described. A method for inducing an immune response against at least two antigens, including the introduction of a recombinant vector or recombinant virus to a patient, is described. A recombinant DNA molecule for the expression of the first and second transgene containing the genome of the recombinant virus is described. A composition for the expression of the first and second transgene containing a recombinant vector or recombinant virus and a pharmacologically acceptable carrier or excipient is described.
EFFECT: invention expands the arsenal of tools for transgene expression.
18 cl, 1 tbl, 4 ex, 5 dwg
